StimOxyGen, a Derry, Northern Ireland, UK-based company developing cancer treatments, raised £1.5M in funding
The round was led by DSW Ventures, with co-investment from QUBIS and Co-Fund NI managed by Clarendon, leveraging additional funding from Innovate UK’s Future Economy Investor Partnership grant programme.
The company intends to use the funds to advance key preclinical studies, scale-up manufacturing, and expand its team as it moves towards clinical translation.
A spin-out from Ulster University is led by CEO Sian Farrell, CSO Professor Anthony McHale, and Non-Executive Director Dr Les Russell, StimOxyGen develops cancer treatments delivering oxygen directly to tumours. Its lead candidate enhances the effectiveness of treatments such as radiotherapy and immunotherapy, offering a potential lifeline for patients with aggressive cancers. The technology directly addresses this issue by increasing tumour oxygenation, making resistant cancers more responsive to standard treatments. Preclinical studies have already demonstrated significant tumour reduction when used in combination with radiotherapy, with promising results across multiple cancer types. The company aims to develop its lead asset as an adjunct therapy to radiotherapy, improving outcomes for patients who currently have few options.
StimOxyGen will initially focus on pancreatic cancer, a disease with a five-year survival rate of just 13% and limited treatment options.
FinSMEs
11/03/2025